WHAT IS CLAIMED:

1. A conjugate comprising poly-D-gamma glutamic acid covalently linked to an immunogenic carrier protein wherein the poly-D-gamma glutamic acid is above about 100 kDa.

2. A conjugate comprising poly-D-gamma glutamic acid covalently linked to an immunogenic carrier protein wherein the poly-D-gamma glutamic acid is above about 200 kDa.

3. A conjugate comprising poly-D-gamma glutamic acid covalently linked to an immunogenic carrier protein wherein the poly-D-gamma glutamic acid is above about 300 kDa.

4. The conjugate according to any of claims 1-3 wherein the poly-D-gamma-glutamic acid is covalently linked to the carrier protein by N-(epsilon-maleimidocaproic acid)hydrazide.

5. The conjugate according to any of claims 1-3 wherein the carrier protein is selected from the group consisting of outer membrane protein complex (OMPC) of *Neiserria meningitides,* tetanus toxoid, diphtheria toxoid, Hepatitis B Surface Antigen (HBsAg), Hepatitis B core antigen (HBcAg), recombinant Protective Antigen or the L1 protein of the Human Papilloma Virus Virus Like Particle type 6, 11 or 16.

6. The conjugate according to any of claims 1-4 wherein the carrier protein is the outer membrane protein complex of *Neiserria meningitidis.*

7. A vaccine comprising a conjugate of any of claims 1-6, an adjuvant and a pharmaceutically acceptable excipient.

8. A vaccine comprising a conjugate of poly-D-gamma glutamic acid covalently linked to the outer membrane protein complex of *Neiserria meningitidis* by N-(epsilon-maleimidocaproic acid)hydrazide, an adjuvant and a pharmaceutically acceptable excipient.

9. A vaccine according to any of claims 7 and 8 further comprising at least one antigen selected from the group consisting of from Haemophilus influenza, hepatitis viruses A, B, or C, epitopes derived from the M2, hemaglutinin and neuraminidase proteins of Influenza virus types A or B, human papilloma virus, measles, mumps, rubella, varicella, rotavirus, *Streptococcus pneumonia* and *Staphylococcus aureus.*

10. A method of vaccinating a patient comprising administering an effective amount of a vaccine of any of claims 7-9.

11. A method of making a conjugate of poly-D-gamma glutamic acid and a carrier protein comprising activating the poly-D-gamma glutamic acid on a portion of its carboxylic acid side chains under non-aqueous conditions, introducing thiol reactive groups at the activated side chains and reacting the thiol reactive groups with a sulfhydryl containing carrier protein.

12. The method according to claim 11 comprising,
providing purified poly-D-gamma glutamic acid as a hydrogen or tertbutylammonium salt, and
removing water from the salt, and
dissolving the salt in an organic solvent, and
mixing the salt with N-(epsilon-maleimidocaproic acid)hydrazide, and
adding an activating agent selected from the group consisting of N,N'-diisopropyl carbodiimide and 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium chloride, and
diluting the reaction, and
dialyzing the reaction; and
adding thiolated outer membrane protein complex, and
quenching residual thiols, and
isolating the conjugate.

13. A method of purifying poly-D-gamma glutamic acid comprising,
dissolve partially purified extract containing poly-D-gamma glutamic acid in water, and
mixing the solution with 0.004M sodium phosphate, pH 7.0 + 1M NaCl, and
load mixture on hydroxyapatite chromatography column, and
washing out non-bound material with 0.004M sodium phosphate, pH 7.0 + 1M NaCl, and
eluting poly-D-gamma glutamic acid with a linear gradient from 0 to 100% 0.4M sodium phosphate, pH 7.0 + 1M NaCl.